Weixiong, as project PC, received RGC Strategic Target Grant (STG) funding (five years and $37 million) to develop AI, genomic and biomedical technologies for developing genetic and neuroimaging markers and integrative approaches for objective diagnosis and personalized therapy of major psychiatric disorders, including depression, schizophrenia, and bipolar disorder.